Paola Pozzi

PinCell Srl is a holding company, which engages in the development of anti-inflammatory therapy for the treatment of orphan diseases of the skin. Its clinical work and research focuses on drug discovery, drug physicochemical characterization, preclinical pharmacology and toxicology studies, and early phase clinical trials on healthy volunteers. The company was founded by Carlo Pincelli and Alessandra Marconi in October 2008 and is headquartered in Milan, Italy.

PinCell Srl is a holding company, which engages in the development of anti-inflammatory therapy for the treatment of orphan diseases of the skin. Its clinical work and research focuses on drug discovery, drug physicochemical characterization, preclinical pharmacology and toxicology studies, and early phase clinical trials on healthy volunteers. The company was founded by Carlo Pincelli and Alessandra Marconi in October 2008 and is headquartered in Milan, Italy.

PinCell Srl is a holding company, which engages in the development of anti-inflammatory therapy for the treatment of orphan diseases of the skin. Its clinical work and research focuses on drug discovery, drug physicochemical characterization, preclinical pharmacology and toxicology studies, and early phase clinical trials on healthy volunteers. The company was founded by Carlo Pincelli and Alessandra Marconi in October 2008 and is headquartered in Milan, Italy.

Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy.

Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy.